Earlier Health Canada Approves Pfizer Canada's Gene Therapy In Hemophilia B
Portfolio Pulse from Benzinga Newsdesk
Health Canada has approved Pfizer Canada's gene therapy BEQVEZ for adults with hemophilia B. The approval is based on the Phase 3 BENEGENE-2 study, which showed potential in reducing the burden of frequent infusions. Over 700 individuals in Canada are affected by hemophilia B. The Canadian Hemophilia Society welcomed the approval and is working to make the therapy accessible across Canada.
January 03, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's gene therapy BEQVEZ for hemophilia B has been approved by Health Canada, indicating a positive development in Pfizer's portfolio of treatments for hematological disorders.
The approval of BEQVEZ by Health Canada is a significant regulatory milestone for Pfizer, likely to have a positive short-term impact on the company's stock as it expands its treatment offerings in the hematology space. The news reflects the company's ongoing commitment to innovation in gene therapy and may increase investor confidence in Pfizer's research and development capabilities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100